WOODCLIFF LAKE, N.J. - Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is confronting potential delisting from the Nasdaq Stock Market after failing to submit required financial reports on time.
The pharmaceutical company disclosed on Monday that it received a notice from Nasdaq's Listing Qualifications Department on May 20, 2024, indicating the initiation of delisting procedures due to the company's non-compliance with filing requirements.
The issue stems from Eagle Pharmaceuticals' delay in filing its Form 10-Q for the quarter ending September 30, 2023, and its Form 10-K for the year ending December 31, 2023.
The company also missed the subsequent deadline for its Form 10-Q for the quarter ending March 31, 2024. According to Nasdaq rules, the company had until May 13, 2024, to file the overdue reports and regain compliance.
Eagle Pharmaceuticals plans to request a hearing before a Nasdaq Hearings Panel to appeal the delisting process. This request will automatically stay the suspension of trading of the company's common stock for 15 calendar days from the date of the request, or potentially 22 calendar days if the request is filed on the last eligible day, May 28, 2024. The company aims to extend this stay through the conclusion of the hearings process.
The Nasdaq Hearings Panel may grant an extension of up to 360 days from the initial due date of the Q3 2023 Form 10-Q for the company to regain compliance.
However, there is no guarantee that the hearing will be successful, that an extended stay or additional extension will be granted, or that Eagle Pharmaceuticals will be able to maintain its Nasdaq listing.
This development follows a series of notifications from Nasdaq regarding the company's filing delays, starting with a delinquency notification on November 27, 2023. Eagle Pharmaceuticals' ability to remedy these issues and maintain compliance with Nasdaq's continued listing requirements remains uncertain.
Eagle Pharmaceuticals, known for its integrated pharmaceutical capabilities, focuses on developing innovative medicines that address underserved therapeutic areas. Its portfolio includes several commercialized products and a pipeline of oncology and CNS/metabolic critical care product candidates.
This report is based on a press release statement and does not include any speculative information about Eagle Pharmaceuticals' future prospects or potential industry-wide implications.
InvestingPro Insights
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is currently navigating challenging financial waters, as reflected in its recent market performance and analyst projections. InvestingPro data reveals a market capitalization of $56.75 million, indicating a relatively small size within the pharmaceutical industry. Despite the company's struggles with Nasdaq listing compliance, the stock is trading at a low revenue valuation multiple, which could signal an undervalued opportunity for investors. In the last twelve months as of Q2 2023, Eagle Pharmaceuticals reported a revenue of $257.55 million, with a notable gross profit margin of 69.84%. However, revenue growth has been negative, with a -5.38% change over the last twelve months and a more pronounced quarterly drop of -12.8% in Q2 2023.
InvestingPro Tips highlight that management has been actively buying back shares, which can be a sign of confidence in the company's future prospects. Additionally, while Eagle Pharmaceuticals has been grappling with a significant debt burden and a rapid cash burn, it's noteworthy that its liquid assets surpass short-term obligations, providing some financial cushion.
For investors seeking more detailed analysis and additional insights, there are currently 11 InvestingPro Tips available for Eagle Pharmaceuticals. These include expectations around profitability for the year and the stock's significant price drop over the last year. To access these insights and enhance your investment strategy, consider subscribing to InvestingPro using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.